LUNG

Pulmonx Corporation (LUNG) Economic Moat Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-09-01

Overall Score

Pricing Power

Gross margin remains high at 77.1%, but persistent negative operating and net margins indicate limited ability to convert pricing into durable profits.

No evidence of a widening moat or sustained premium pricing from the latest financials.

Scale Efficiency

Revenue per share is only 2.07, while SG&A to revenue is elevated at 107.9%, suggesting weak scale leverage.

Asset turnover is 0.76, but the business still fails to translate scale into operating profitability.

Switching Costs

The latest data does not show customer lock-in or recurring revenue characteristics that would imply meaningful switching costs.

Negative operating cash flow and margins suggest the company is not yet benefiting from sticky demand.

Intangible Assets

Intangibles are only 2.0% of total assets, and there is no fresh evidence of brand or IP strength supporting a moat.

High gross margin alone is not enough to confirm durable intangible advantages.

Network Effects

No signs of network effects are visible in the current metrics or news flow.

The business appears to compete without platform-like compounding advantages.

Cost Advantage

Operating costs remain heavy, with negative EBIT margin of -50.0% and SG&A above revenue, arguing against a cost moat.

Inventory days of 298 and a cash conversion cycle of 264 days point to inefficient working-capital dynamics.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Pulmonx Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →